Loading…
Loading…
Biogen Inc
NASDAQ · Stock Profile · Market Cap $26.75B
Current Price
$182.31
-1.61%GoodMoat Value
$278.19
52.6% undervaluedProfit margin stands at 13.1%.
Forward estimates use 19.7% FCF growth (CAGR)
Net Debt: 3.6B
2.5B
FY24
2.5B
FY24
9.7B
FY24
2.4B
FY25
2.6B
FY25
2.5B
FY25
9.9B
FY25
584M
FY24
389M
FY24
1.6B
FY24
241M
FY25
635M
FY25
467M
FY25
1.3B
FY25
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. 4. About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care ( hhc ) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Country
Massachusetts, USA
Trading 53% below its estimated fair value of $278.19.
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Run a full DCF analysis with customizable assumptions
Open DCF Calculator →Graham Number, PEG-based, and Earnings-based models
View Fair Value →This stock does not currently pay a dividend.
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. 4. About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care ( hhc ) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Country
Massachusetts, USA